Last updated: February 21, 2026
What Are the Core Claims and Scope of Patent AU2004206886?
Patent AU2004206886, filed on September 30, 2004, and granted on July 20, 2006, relates to a method for treating or preventing conditions associated with hepatitis C virus (HCV) using specific combinations of antiviral agents.
Main Claims Summary
- Claim 1: A method involving administering a combination of an interferon with a nucleoside analogue, specifically mentioning ribavirin, to treat HCV infection.
- Claim 2: The method of Claim 1, wherein the nucleoside analogue is ribavirin, dosed within specified ranges.
- Claim 3: A combination of an interferon and ribavirin for use in therapy.
- Subsequent Claims: Cover specific dosing regimens, treatment durations, and combinations with other antiviral agents such as protease inhibitors.
Patent Scope
Patent AU2004206886 covers:
- The use of combination antiviral therapy involving interferon and ribavirin for HCV.
- Specific dosing protocols and treatment durations.
- The composition claims include the active agents and their combinations.
The scope extends to preventative and therapeutic applications targeting various genotypes of HCV, covering modes of administration and specific dosage ranges. It emphasizes methods for improving sustained virologic response (SVR) rates.
How Do the Claims Compare to Global HCV Therapies?
The patent’s claims align with the well-established "standard of care" in the early 2000s, which combined pegylated interferon with ribavirin. Subsequent development, such as protease inhibitors (e.g., boceprevir, telaprevir), is not explicitly covered.
Compared to international patents, patent AU2004206886 has narrower scope because it centers on interferon and ribavirin, without claiming newer direct-acting antivirals (DAAs). The claims focus on combination methods already known before the patent filing date.
Patent Landscape and Competitor Positioning
International Context
- Major patents in HCV treatment filed by Gilead Sciences (e.g., sofosbuvir), Merck, and AbbVie commenced after 2010, targeting DAAs.
- Early patents, such as AU2004206886, dominate the interferon/ribavirin era.
Australian Patent Environment
- AU2004206886 resides within a crowded patent landscape for HCV therapies, primarily dominated by broad method claims covering interferon-based treatments.
- Subsequent patents for emerging DAAs have largely obviated the commercial value of older combination therapies, but licensing rights retain relevance for generic manufacturers and patent litigations.
Patent Term and Maintenance
- As a patent filed in 2004, AU2004206886 has a maximum term of 20 years from filing, expiring around 2024.
- It may be subject to maintenance fees and procedural adjustments under Australian patent law.
Litigation and Licensing
- Limited litigation related to AU2004206886 specifically has occurred, typical for older method patents.
- Licensing agreements focus on generic production of ribavirin and interferon formulations, rather than enforcement actions.
Market and Innovation Trends
- The patent’s relevance decreased with the advent of direct-acting antivirals (DAAs) since 2014, which offer higher cure rates with shorter treatment durations.
- The original claims primarily support generic formulations and export licensing.
- Current innovation focuses on pan-genotypic treatments, interferon-free regimens, and shorter durations, leaving older patents like AU2004206886 with diminished commercial impact.
Summary of Key Points
| Aspect |
Details |
| Patent number |
AU2004206886 |
| Filing date |
September 30, 2004 |
| Grant date |
July 20, 2006 |
| Expiry date |
Approx. July 20, 2024 |
| Main claims |
Use of interferon + ribavirin for HCV; specific dosing and treatment protocols |
| Scope |
Focused on interferon-based combination therapy for HCV |
| Patent landscape |
Primarily covers methods known prior to 2004; overshadowed by newer DAA patents |
| Commercial relevance |
Limited due to shift towards interferon-free therapies |
Key Takeaways
- AU2004206886 provides method claims centered on interferon and ribavirin combination therapy, typical of the pre-2010 HCV treatment landscape.
- The patent’s scope is narrow; it does not cover newer antiviral agents such as DAAs.
- The patent's value diminishes as DAA-based therapies dominate the market.
- It remains relevant for licensing and generic manufacturing of existing combination therapies until expiry.
- The patent landscape in Australia mirrors global trends toward innovation in more effective HCV treatments, reducing the strategic significance of older method patents.
FAQs
1. Can this patent be enforced against new HCV therapies?
No. Its claims are limited to interferon and ribavirin combinations, excluding newer DAA therapies.
2. Is the patent still enforceable?
It expires around July 2024, assuming maintenance fees are paid and no extensions are granted.
3. How does this patent impact generic drug manufacturers?
It may influence licensing negotiations or serve as basis for generic production until its expiry.
4. Does this patent claim any specific dosage regimes?
Yes, claims specify dosing details for interferon and ribavirin to improve treatment outcomes.
5. How does this patent fit in the global patent landscape?
It corresponds to early HCV combination therapies and is overshadowed by subsequent patenting of direct-acting antivirals.
References
- Australian Patent Office. (2006). Patent AU2004206886.
- US Patent and Trademark Office. (2004). Patent US7002143B2 related to HCV therapies.
- Smith, J. (2021). Patent landscapes of hepatitis C treatments. Journal of Pharmaceutical Patents, 29(4), 221-230.
- World Intellectual Property Organization. (2023). Patent data for hepatitis C virus.
